Skip to main content
. 2018 Dec 19;43(9):1839–1848. doi: 10.1038/s41366-018-0288-6

Fig. 2.

Fig. 2

Annual prescription costs attributable to excess weight among women aged 55–79 years in England, by category of therapeutic use. Medications were categorised by therapeutic use (defined by BNF chapters or sections), and ordered here according to their contribution to overweight and obesity attributable costs. These estimates were derived by applying the estimates of excess costs by BMI category for each therapeutic use category from the Million Women Study analysis to women aged 55–79 in England using the Health Surveys for England 2012 and 2013 to estimate the population level distribution of women by self-reported BMI category and ONS mid-2013 population estimates. Excess costs were calculated relative to a BMI category of 20–24.9, estimated as a weighted average of the estimates of the two sub-categories (20 to <22.5 and 22.5 to <25)